For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Europe chronic idiopathic constipation drug market is estimated to grow at a CAGR of 8.80% during the forecast years of 2017-2025.The market value is estimated to increase from $1283 million in 2016 and reach $2721 million by 2025.
The market has plenty of growth opportunities owing to the unmet needs of CIC drugs in certain countries. The market can be segmented into two types on the basis of the type of prescriptions and the type of drugs. The type of prescriptions can be further divided into over the counter drugs and the doctor prescribed ones. The drug types are mainly subdivided into linaclotide and lubiprostone. Lubiprostone is the leading drug in the market.
The top players in the market include Progenics Pharmaceuticals Inc, Theravance Biopharma Inc, Cosmo Pharmaceuticals Sa, Valeant Pharmaceuticals International, Daiichi Sankyo Co Ltd, Ironwood Pharmaceuticals Inc, Salix Pharmaceuticals Ltd, Sucampo Pharmaceuticals Inc,Eli Lilly And Company, Bayer Ag, Merck Sharp & Dohme,Roche Holding Ag, Pfizer, GlaxoSmithKline,Synergy Pharmaceuticals, Chugai Pharmaceutical, Allergens and Ferring International Center S.A.